Zealand Pharma AS ZEAL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Zealand Pharma to participate in the 2024 Cantor Global Healthcare Conference on September 18th
-
Zealand Pharma announces positive topline results from 13-week Phase 1b multiple ascending dose clinical trial with GLP-1/GLP-2 receptor dual agonist dapiglutide
-
Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say
-
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants
-
Zealand Pharma Announces Financial Results for the First Half of 2024
-
Zealand Pharma conference call on August 15 at 2pm CET (8am ET) to present first half 2024 financial results
-
Zealand Pharma Appoints Eric Cox as Chief Commercial Officer
-
Roche obesity-pill trial results weigh on shares of Eli Lilly, Novo Nordisk
Trading Information
- Previous Close Price
- DKK 830.50
- Day Range
- DKK 805.50–827.00
- 52-Week Range
- DKK 274.40–972.00
- Bid/Ask
- DKK 816.50 / DKK 817.50
- Market Cap
- DKK 57.96 Bil
- Volume/Avg
- 192,714 / 319,641
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 133.77
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 288
- Website
- https://www.zealandpharma.com
Comparables
Valuation
|
Metric
|
ZEAL
|
NOVO B
|
AUPH
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 39.67 | — |
Price/Book Value | 6.17 | 31.53 | 2.85 |
Price/Sales | 133.77 | 13.82 | 5.05 |
Price/Cash Flow | — | 31.53 | — |
Price/Earnings
ZEAL
NOVO B
AUPH
Financial Strength
|
Metric
|
ZEAL
|
NOVO B
|
AUPH
|
|---|---|---|---|
Quick Ratio | 35.34 | 0.74 | 4.63 |
Current Ratio | 35.57 | 0.94 | 5.33 |
Interest Coverage | −10.81 | 30.52 | −11.69 |
Quick Ratio
ZEAL
NOVO B
AUPH
Profitability
|
Metric
|
ZEAL
|
NOVO B
|
AUPH
|
|---|---|---|---|
Return on Assets (Normalized) | −14.29% | 28.75% | −2.14% |
Return on Equity (Normalized) | −16.41% | 89.64% | −3.06% |
Return on Invested Capital (Normalized) | −16.01% | 67.68% | −4.73% |
Return on Assets
ZEAL
NOVO B
AUPH
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Jqkmnbrlkf | Zzwzk | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Ytkwpmjw | Xjzvtwy | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Bndpjvbj | Ppqhmm | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Frysnbdm | Gnqhgd | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Ptvvzmslw | Gdsz | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Pcpqlrv | Xlbkj | $28.1 Bil | |||
| Moderna Inc
MRNA
| Vtzhqcbwc | Fht | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Vbnpmssm | Stxj | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Mklnvnr | Dshrnbt | $13.4 Bil | |||
| Incyte Corp
INCY
| Hqdtytdy | Zbgshvh | $12.7 Bil |
United States